Issued Patents All Time
Showing 1–14 of 14 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 11266700 | Compositions and methods for treating immune disorders using immune modulating Lactococcus bacteria strains | Brian Goodman, Holly Ponichtera, Andrea Itano, Taylor A. Cormack, Maria Sizova +3 more | 2022-03-08 |
| RE39548 | Interleukin-5 specific recombinant antibodies | Diljeet Singh Athwal, John Spencer Emtage | 2007-04-03 |
| 6734286 | Interleukin-5 specific recombinant antibodies | Diljeet Singh Athwal, John Spencer Emtage | 2004-05-11 |
| 6316227 | Nucleic acids encoding interleukin-5 specific recombinant antibodies | Diljeet Singh Athwal, John Spencer Emtage | 2001-11-13 |
| 6315999 | Pharmaceutical product for the treatment of sepsis | Jerald C. Sadoff, Steven M. Opal, Alan Cross | 2001-11-13 |
| 6180377 | Humanized antibodies | Susan Adrienne Morgan, John Spencer Emtage, Diljeet Singh Athwal | 2001-01-30 |
| 6013642 | Use of estrone derivatives as steroid sulphatase inhibitors | Roland Foulkes, John Spencer Emtage, Martin Rae Wales, Graham A. W. Rook | 2000-01-11 |
| 5998586 | Interleukin-5 specific recombinant antibodies | Diljeet Singh Athwal, John Spencer Emtage | 1999-12-07 |
| 5994510 | Recombinant antibodies specific for TNF.alpha. | John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage | 1999-11-30 |
| 5965405 | Method for producing Fv fragments in eukaryotic cells | Gregory Paul Winter, Lutz Riechmann, Geoffrey T. Yarranton, Raymond John Owens | 1999-10-12 |
| 5958413 | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor | Hiristo Anagnostopulos, Ulrich Gebert, Heinz Hanel, Michael Limbert, Gerald Anthony Higgs | 1999-09-28 |
| 5877293 | CDR grafted anti-CEA antibodies and their production | John Robert Adair, Andrew Mountain, Raymond John Owens | 1999-03-02 |
| 5677425 | Recombinant antibody | John Robert Adair, Nigel Richard Whittle | 1997-10-14 |
| 5219996 | Recombinant antibodies and methods for their production in which surface residues are altered to cysteine residues for attachment of effector or receptor molecules | John Robert Adair, Nigel Richard Whittle, Alan Howard Lyons, Raymond John Owens | 1993-06-15 |